Dengue fever in a multiple sclerosis patient taking ocrelizumab: Clinical commentary

World Health Organization. Dengue: Guidelines for diagnosis, treatment, prevention and control. Geneva: World Health Organization, 2009.

Guerra T Bollo L Trojano M , et al. Dengue fever in a multiple sclerosis patient taking ocrelizumab. Mult Scler 2021; 27(13): 2116–2118.

Simmons M Burgess T Lynch J , et al. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010; 396(2): 280–288.

Yauch LE Zellweger RM Kotturi MF , et al. A protective role for dengue virus-specific CD8+ T cells. J Immunol 2009; 182(8): 4865–4873.

Bar-Or A Calkwood JC Chognot C , et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study. Neurology 2020; 95(14): e1999–e2008.

Fragoso YD da Gama PD Gomes S , et al. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Mult Scler Relat Disord 2016; 6: 64–65.